Heart shield: diabetes drug may prevent Chemo-Induced cardiac damage
NCT ID NCT05271162
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The goal is to see if the drug helps maintain heart function and reduce serious heart-related events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology and Transfusion Medicine
Warsaw, Poland
-
National Institute of Oncology
Warsaw, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- A virtual Walk-Through of radiotherapy may calm cancer Patients' nerves
- Money worries and cancer: can talking about both ease the burden?
- Digital navigator aims to cut financial toxicity for young adults with cancer
- Can a simple checklist boost recovery after cancer surgery?
- Leftover blood samples could unlock new medical discoveries